This dataset contains anonymised human lung computed tomography (CT) scans with COVID-19 related findings, as well as without such findings. A small subset of studies has been annotated with binary pixel masks depicting regions of interests (ground-glass opacifications and consolidations). CT scans were obtained between 1st of March, 2020 and 25th of April, 2020, and provided by municipal hospitals in Moscow, Russia. Permanent link: https://mosmed.ai/datasets/covid19_1110. This dataset is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0) License.
With the ongoing COVID-19 pandemic decreasing availability of polymerase chain reaction with reverse transcription and the snowballing growth of medical imaging, especially the number of chest computed tomography (CT) scans being performed, methods to augment and automate the image analysis, increasing productivity and minimizing human error are of particular importance. The creation of high-quality datasets is essential for the development and validation of artificial intelligence algorithms. Such technologies have sufficient accuracy in diagnosing COVID-19 in medical imaging. The presented large-scale dataset contains anonymized human CT scans with COVID-19 features as well as normal studies. Some studies were tagged by radiologists using binary pixel masks of regions of interest (e.g., characteristic areas of consolidation and ground-glass opacities). CT data were acquired between March 1, 2020, and April 25, 2020, and provided by municipal hospitals in Moscow, Russia. The presented dataset is licensed under Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0).
BACKGROUND:In the current epidemiological situation, computed tomography (CT) of chest organs plays an important role in disease diagnosis. Clinical and CT data allow physicians to quickly establish the probability of the presence and prognosis of patients with coronavirus disease 2019 (COVID-19).
AIMS:This study aimed to predict outcomes in patients with laboratory-confirmed COVID-19 based on chest CT and a semi-quantitative visual pulmonary lesion grading system (CT 04).
MATERIALS AND METHODS:A retrospective analysis of the Unified Medical Information and Analytical Service and Unified Radiological Information Service records from March 01, 2020 to July 30, 2020 was performed. The inclusion criteria were as follows: patients diagnosed with U07.1 (laboratory-verified coronavirus infection) from March 01, 2020 to July 30, 2020 and referred for a chest CT by a physician with suspected community-acquired pneumonia caused by COVID-19; the maximum period between laboratory verification and CT was not more than five days. The observation period for each patient was at least till 30 days from the date of CT. CT was performed in 48 medical organizations providing primary medical care to adults in Moscow. The exclusion criterion was a negative reverse transcription-polymerase chain reaction results by July30, 2020. The CT 04 scale is recommended for use in the Russian Federation to estimate the volume of lung parenchyma lesions when COVID-19 is suspected.
RESULTS:The total sample volume was 38,051 patients. In this study, the risk of death was three times higher for CT-4 than for CT-0. In the KaplanMeier survival curve, the survival rate of patients in the CT-3 category was almost three times lower (hazard ratio = 2.94) than in the CT 02 categories; in addition, the higher the initial category of CT, the lower the risk of deterioration. The time for hospitalization decreased with the increase in the CT grade.
CONCLUSION:The visual CT 04 scale can be used to predict outcomes, such as hospitalizations and deaths, in patients suspected of COVID-19 who underwent chest CT in primary health care.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.